Kenvue Inc (KVUE)

Currency in USD
18.98
-0.07(-0.37%)
Closed·
19.03+0.05(+0.26%)
·
Advertisement
High dividend Yield
KVUE is not included in our AI-picked strategies. See which stocks are.
Fair Value
Day's Range
18.6519.06
52 wk Range
14.0221.84
Key Statistics
Prev. Close
18.98
Open
18.69
Day's Range
18.65-19.06
52 wk Range
14.02-21.84
Volume
11.03M
Average Volume (3m)
20.8M
1-Year Change
-12.5749%
Book Value / Share
5.5
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
KVUE Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Price Target
19.50
Upside
+2.74%
Members' Sentiments
Bearish
Bullish
ProTips
Has raised its dividend for 3 consecutive years

Kenvue Inc News & Analysis

Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Neutral
Technical Indicators
Buy
Moving Averages
Strong Sell

Analyst Ratings

2 Buy
12 Hold
0 Sell
Ratings:
14 analysts
Overall Consensus
Neutral

Analysts 12-Month Price Target:

Average 19.50
(+2.74% Upside)
Firm
ArticlePositionPrice TargetUpside / DownsideFrom Price TargetActionDate
Barclays
Hold19.00+0.11%18.00Maintain21/07/2026
UBS
Hold20.00+5.37%18.00Maintain16/07/2026
Barclays
Hold18.00-5.16%19.00Maintain15/04/2026
UBS
Hold18.00-5.16%19.00Maintain07/04/2026
Barclays
Hold19.00+0.11%18.00Maintain05/03/2026

Kenvue Inc SWOT Analysis


Tylenol Turmoil
Explore the impact of acetaminophen controversy on Kenvue's market position and the potential long-term implications for its flagship brand
Financial Headwinds
Kenvue faces challenges across all segments, with revised 2025 outlook projecting low-single-digit declines in organic sales, down from previous growth estimates
Strategic Shift
Delve into Kenvue's new management initiatives, focusing on operational simplification and innovation to drive growth and address underperformance in key segments
Valuation Insights
Analysts set average price target of $23.20, with estimates ranging from $18 to $29, reflecting diverse views on Kenvue's growth potential and market challenges
Read full SWOT analysis

Kenvue Inc Earnings Call Summary for Q2/2025

  • Q2 2025 adjusted EPS of $0.29 missed expectations by 17.14%, revenue of $3.84B fell short by 8.13%
  • Stock rose 1.45% pre-market despite earnings miss; organic sales declined 4.2% in Q2
  • Full-year 2025 guidance: organic sales to decline low single digits, adjusted EPS projected at $1.00-$1.05
  • Company focusing on largest brands, innovation, and operational efficiency amid cautious consumer sentiment
  • Considering strategic alternatives to streamline operations; 83% of U.S. business holding or gaining market share
Last Updated: 07/08/2025, 18:12
Read Full Transcript

Earnings

Latest Release
06/08/2026
EPS / Forecast
0.31 / 0.32
Revenue / Forecast
3.96B / 3.97B
EPS Revisions
Last 90 days

Dividends

Payout Ratio
Payout ratio (TTM)
Earnings retained
EPS 0.85%
Dividend Yield
4.41%
Industry Median 2.73%
Annualised payout
0.84
Paid quarterly
5-Years Growth
-
Growth Streak

Kenvue (KVUE) Income Statement & Profits

Compare KVUE to Peers and Sector

Metrics to compare
KVUE
Peers
Sector
Relationship
P/E Ratio
22.0x19.7x11.6x
PEG Ratio
1.490.170.03
Price/Book
3.5x2.2x1.5x
Price / LTM Sales
2.4x1.9x0.9x
Upside (Analyst Target)
0.1%17.8%23.4%
Fair Value Upside
Unlock13.0%13.9%Unlock

Kenvue Inc. operates as a consumer health company in the United States, rest of North America, Europe, the Middle East, Africa, the Asia-Pacific, and Latin America. It operates in three segments: Self Care, Skin Health and Beauty, and Essential Health. The company offers over-the-counter medicine for cough, cold and allergy, pain care, digestive health, smoking cessation, and eye care, as well as other naturally inspired and self-care products, digital diagnostics, and telemedicine; face and body care, hair, sun, and other care products; oral and baby care, women’s health, wound care, and other essential health products; tampons; cosmetics; and vitamins and supplements. It sells its products under the Benadryl, Calpol, Motrin, Nicorette, Rhinocort, Tylenol, Zarbee’s Naturals, and Zyrtec; Aveeno, Dr.Ci:Labo, Le Petit Marseillais, Lubriderm, Neutrogena, OGX, and Rogaine; BAND-AID, Carefree, Desitin, Johnson’s, Listerine, o.b., and Stayfree; and ORSL, Clean & Clear, Versalie, Benylin, Daktarin, Imodium, Johnson’s Baby, Johnson’s Adult, Maui Moisture, Microlax, Motilium, Neosporin, Neostrata, Pepcid, Pulmicort, Regaine, Sudafed, and Visine/Vispring/Visclear brands. Kenvue Inc. was incorporated in 2022 and is headquartered in Summit, New Jersey.

Ownership

Ownership Overview

Type
Common Stock Held% of Shares OutstandingMarket Value
Mutual Funds & ETFs
866.37M45.11%16.44B
Other Institutional Investors
968.45M50.42%18.38B
Public Companies & Retail Investors
85.96M4.48%1.63B
Total
1.92B100.00%36.46B

Top Holders

Holder
% of holding
Shares Held
Date Reported
Value (In 1,000s)
BlackRock, Inc.7.56%145,297,2922,757,743
Vanguard Capital Management, LLC7.04%135,204,9172,566,189

People Also Watch

92.50
ECHO
+5.14%
32.74
GDS
+0.34%
6.74
CXM
-1.89%

FAQ

What Is the Kenvue (NYSE: KVUE) Share Price Today?

The Kenvue stock price today is 18.98 USD.

What Stock Exchange Does Kenvue (KVUE) Trade On?

Kenvue is listed and trades on the New York Stock Exchange.

What Is the Ticker (Stock Symbol) for Kenvue?

The stock symbol (also called a 'ticker') for Kenvue is "KVUE."

Does Kenvue Pay Dividends? What’s The Current KVUE Dividend Yield?

Yes, KVUE Pays Dividends to its Shareholders. The current Kenvue dividend yield is 4.41%.

What Is the Current Kenvue Market Capitalisation?

As of today, Kenvue (NYSE: KVUE) market cap is 36.46B USD.

What Is Kenvue's (KVUE) Earnings Per Share (TTM)?

The Kenvue EPS is currently 0.85 (Trailing Twelve Months).

When Is the Next Kenvue Earnings Date?

Kenvue's next earnings report will be released on 11/11/2026.

Is KVUE a Buy or Sell From a Technical Analyst Perspective?

Based on today's Kenvue moving averages and other technical indicators, the daily buy/sell signal for KVUE stock is Neutral.

How Many Times Has Kenvue Stock Split?

Kenvue has split 0 times. (See the KVUE stock split history page for full effective split date and price information.)

How Many Employees Does Kenvue Have?

Kenvue has 21890 employees, based on their latest Companies House report.

What is the current trading status of Kenvue (NYSE: KVUE)?

As of 13/08/2026, Kenvue (KVUE) is trading at a share price of 18.98 USD, with a previous close of 18.98 USD. The stock has fluctuated within a day range of 18.65 USD to 19.06 USD, while its 52-week range spans from 14.02 USD to 21.84 USD.

What Is Kenvue (KVUE) Price Target According to Analysts?

The average 12-month price target for Kenvue is 19.50 USD, with a high estimate of 23 USD and a low estimate of 18 USD. 2 analysts recommend buying the stock, while 0 suggest selling, leading to an overall rating of Neutral. The stock has an +2.74% Upside potential.

What Is the KVUE After Hours Price?

KVUE's last after hours stock price is 19.01 USD, the stock has decreased by 0.03, or 0.14%.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.